Array Biopharma ARRY shares are up over 5 percent in Monday's afternoon session as the earlier Amgen AMGN, Onyx ONXX bid and the Celgene CELG MorphoSys partnership signals significant interest in the multiple myeloma space, according to Wells Fargo's Matthew Andrews.
The analyst believes Array's ARRY-520 is an under-appreciated asset in this field.
Andrews maintains an Outperform rating on shares of Array Biopharma.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst Ratings
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in